Fig. 7: Clinical utility of plasma p-tau212 and p-tau217 in a real-world memory clinic cohort.

Clinical validation of the plasma p-tau212 assay versus p-tau217 in the Slovenia memory clinic cohort. a Plasma p-tau212 levels in the different diagnostic groups – SCD (Subjective Cognitive Decline) (n = 24), non-AD MCI (non-Alzheimer’s Disease Mild Cognitive Impairment) (n = 20), AD MCI (Alzheimer’s Disease Mild Cognitive Impairment) (n = 41), AD dementia (Alzheimer’s Disease Dementia) (n = 62), and b Plasma p-tau217 levels in the different diagnostic groups – SCD (n = 24), non-AD MCI (n = 21), AD MCI (n = 41), AD Dementia (n = 60) levels in the different diagnostic groups. The SCD and non-AD MCI groups included Aβ-negative participants while the AD MCI and AD dementia groups were all Aβ-positive. c Concordance between plasma p-tau212 and p-tau217. Percentage of concordant measurements are given in the lower left and upper right quadrants whilst the percent of discordant cases are in the lower right and upper left quadrants. Assay cut-offs were estimated using the Youden’s index. d Area under the curve (AUC) comparison of plasma p-tau212 and plasma p-tau217 to differentiate between SCD and AD-dementia. e AUC comparison of plasma p-tau212 and plasma p-tau217 measurements to differentiate between non-AD MCI and AD-dementia participants. De Long’s test comparisons of the AUCs did not reveal any significant differences. Box plots are shown as median and interquartile ranges (IQR), boundaries of the whiskers are minimum and maximum values. Group differences were examined using Dwass-Steel-Critchlow-Fligner test. Source data are provided as a Source Data file.